TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31781100
Drug: Vi-TT vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-TT vaccine
Study: 29722285
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 0.5 µg/kg/minute (Group R 0.5)
Study: 29722285
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 1.0 µg/kg/minute (Group R 1.0)
Study: 29722285
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (Group S)
Study: 27454267
Drug: Optimized conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized conventional treatment
Study: 22801581
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 μg kg(‐1)
Study: 22801581
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 μg kg(‐1)
Study: 22801581
Drug: Remifentanil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 3 μg kg(‐1)
Study: 20934602
Drug: Preexercise supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preexercise supplement (Game Time; containing caffeine, creatine, and amino acids)
Study: 20934602
Drug: Preexercise supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preexercise supplement (Game Time)
Study: 8549030
Drug: Netivudine 400
Normalized name: Netivudine
DrugBank: Netivudine (DB12606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netivudine 400 mg
Study: 8549030
Drug: Netivudine 800
Normalized name: Netivudine
DrugBank: Netivudine (DB12606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netivudine 800 mg
Study: 28270164
Drug: pegcantratinib (TRK
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegcantratinib (TRK inhibitor) applied topically for 12 weeks
Study: 28270164
Drug: pegcantratinib (TRK
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegcantratinib (TRK inhibitor) applied topically for 4 weeks
Study: 28270164
Drug: pegcantratinib (TRK
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegcantratinib (TRK inhibitor) and placebo
Study: 23806846
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa; 0.2 mg triptorelin) and standard LPS
Study: 23806846
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (0.2 mg triptorelin) and standard LPS
Study: 23806846
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (0.2 mg triptorelin) without LPS
Study: 16781361
Drug: eptifibatide/reduced-dose unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: eptifibatide/reduced-dose unfractionated heparin
Study: 16781361
Drug: eptifibatide/reduced-dose enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: eptifibatide/reduced-dose enoxaparin
Study: 10634368
Drug: Spironolactone, flutamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, flutamide, or finasteride (active drugs)
Study: 9198827
Drug: Nicergoline (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (8 mg i.v. for 5 days, then 30 mg oral for 25 days)
Study: 9198827
Drug: Pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200 mg i.v. for 5 days, then 800 mg oral for 25 days)
Study: 8497681
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms salbutamol inhaled 10 min before sBPT (treatment A)
Study: 8497681
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms salbutamol inhaled 2 h before sBPT (treatment B)
Study: 8497681
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation 10 min before sBPT (treatment A)
Study: 8497681
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation 2 h before sBPT (treatment B)
Study: 3518726
Drug: Ibopamine in
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine in association with digitalis and diuretics (10 patients, Group 1)
Study: 3518726
Drug: Digitalis and
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis and diuretics (8 patients, Group 2)
Study: 29406465
Drug: Daptomycin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (7 mg/kg for 12-17 years, 9 mg/kg for 7-11 years, 12 mg/kg for 1-6 years)
Study: 27124034
Drug: Deep group
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep group (LMA removed under deep anesthesia with propofol at 2 μg/mL)
Study: 22276745
Drug: Immediate salvage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate salvage therapy (no-ARDFP group)
Study: 22276745
Drug: ARV drug-free
Normalized name: Arv-110 (protac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV drug-free period (ARDFP)
Study: 19625976
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) ingestion at a dosage of 0.3 g.kg(‐1) body weight (BW)
Study: 19625976
Drug: NaCl placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl placebo (PLAC) at a dosage of 0.045 g.kg(‐1) BW
Study: 14991337
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A treatment
Study: 19050545
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A combined with other treatment modalities
Study: 19050545
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A treatment across multiple facial areas
Study: 15857066
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (bioabsorbable membranes with a bone replacement graft)
Study: 10440429
Drug: Aspirin (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (active control)
Study: 2014712
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nicergoline once daily
Study: 2014712
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg co-dergocrine mesilate once daily
Study: 31856887
Drug: Twice-daily nebulised
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily nebulised hypertonic saline (HTS 6%)
Study: 31856887
Drug: Carbocisteine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day)
Study: 31856887
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of twice-daily nebulised HTS and carbocisteine
Study: 17631079
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control (attempting to maintain sinus rhythm, principally with antiarrhythmic drugs)
Study: 11057794
Drug: Meropenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (500 mg) administered intravenously every 12 hrs
Study: 9493076
Drug: High-dose growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose growth hormone (GH) treatment, daily s.c. dose of either 0.2 or 0.3 IU/kg for 2 years
Study: 9493076
Drug: High-dose growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose growth hormone (GH) treatment
Study: 3531567
Drug: Ceftizoxime suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime suppository (CZX‐S), 250 mg, four times daily for 7 days
Study: 3531567
Drug: Ceftizoxime intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime intravenous injection (CZX), 60 mg/kg body weight, four times daily for 7 days
Study: 3531567
Drug: Ceftizoxime suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime suppository (CZX‐S)
Study: 3531567
Drug: Ceftizoxime intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime intravenous injection (CZX)
Study: 30289435
Drug: MK-2048 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2048 (30 mg) and vicriviroc (VCV, 182 mg) vaginal rings used continuously for 28 days
Study: 30022409
Drug: Patient-family agenda
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-family agenda setting intervention (self-administered paper-pencil checklist)
Study: 26184078
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg melatonin
Study: 22348831
Drug: 0.4% L-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% L-menthol (n = 32)
Study: 22348831
Drug: 0.8% L-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% L-menthol (n = 35)
Study: 22348831
Drug: 1.6% L-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6% L-menthol (n = 30)
Study: 45587
Drug: Dihydrocodeine 60
Normalized name: dihydrocodeine bitartrate 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine 60 mg
Study: 9473085
Drug: Nucleus 22
Normalized name: SUS SCROFA THALAMUS LATERAL GENICULATE NUCLEUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus 22 and Med-El Combi 40 cochlear implants
Study: 2474103
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dietary sodium restriction and ACE inhibitors
Study: 2474103
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of a thiazide diuretic
Study: 320712
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with factor VIII or factor IX concentrate and a reducing dose of prednisolone
Study: 26333778
Drug: Standard antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antimicrobial therapy plus daily granulocyte transfusions from donors stimulated with G-CSF and dexamethasone
Study: 26333778
Drug: Standard antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antimicrobial therapy
Study: 21608218
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies (Control group)
Study: 15083284
Drug: Natalizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab (3 mg/kg or 6 mg/kg)
Study: 7948819
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acid solution (Aminoleban), intravenous infusion for 3 hours
Study: 29274894
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of telephone counseling with the internet-based walking program
Study: 27528177
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg 3 times daily for 2 weeks
Study: 27528177
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 times daily for 2 weeks
Study: 19108789
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (T4 Montpellier 100)
Study: 19108789
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Synthroid)
Study: 19108789
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (T4 Montpellier 100) with baseline adjustment
Study: 19108789
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Synthroid) with baseline adjustment
Study: 15996609
Drug: Heat wrap
Normalized name: Softheat Ultra Back Heat Wrap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat wrap therapy alone (n=25)
Study: 15996609
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of heat wrap therapy and exercise (heat+exercise, n=24)
Study: 8694321
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg daily
Study: 26051022
Drug: Telephone-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive-behavioral therapy (CBT) intervention
Study: 23515142
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg per kg bodyweight intravenously every 4 weeks plus placebo subcutaneously every 2 weeks
Study: 23515142
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg subcutaneously every 2 weeks plus placebo intravenously every 4 weeks
Study: 10350034
Drug: Buspirone (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (20-60 mg/day, mean daily dose 48.5 mg)
Study: 8606118
Drug: Bivalent vaccine
Normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent vaccine composed of Vibrio cholerae CVD 103‐HgR and Salmonella typhi Ty21a
Study: 1954640
Drug: 0.025% capsaicin
Normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% capsaicin cream applied four times daily for four weeks
Study: 7318332
Drug: Dihydralazine (16.2‐32.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (16.2‐32.4 mg/2 h) plus saline
Study: 7318332
Drug: Dihydralazine (16.2‐32.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (16.2‐32.4 mg/2 h) plus diclofenac (75 mg/20 ml saline)
Study: 6499689
Drug: Meclozine tablets
Normalized name: meclozine
DrugBank: Meclizine (DB00737)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclozine tablets
Study: 24377410
Drug: modified cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified cognitive behavioral therapy (m-CBT)
Study: 24377410
Drug: usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual care (UC) therapy
Study: 19533356
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg by mouth every morning)
Study: 19533356
Drug: Aerosolized, swallowed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized, swallowed fluticasone (440 mcg by mouth twice a day)
Study: 12599218
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy for Stage II breast carcinoma
Study: 19496252
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine
Study: 7109137
Drug: Individualized method
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized method for calculating gentamicin dosage
Study: 31238081
Drug: Soy beverage
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy beverage (200 ml consumed once a day for 15 days)
Study: 31238081
Drug: Bovine milk
Normalized name: Bovine Milk Plasma
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine milk (200 ml consumed once a day for 15 days)
Study: 21719715
Drug: Combined clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined clinic (CC)
Study: 20649426
Drug: Acyclovir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (400 mg, twice daily)
Study: 18041171
Drug: Grazax (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazax (oral vaccine)
Study: 9917081
Drug: Tramadol titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol titrated at 10 days to achieve 200 mg/day
Study: 9917081
Drug: Tramadol titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol titrated at 4 days to achieve 200 mg/day
Study: 9917081
Drug: Tramadol titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol titrated at 1 day to achieve 200 mg/day
Study: 1962781
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy and thoracic irradiation
Study: 7282733
Drug: Oral aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aminophylline (0.4 to 0.6 g)
Study: 7282733
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both (aminophylline and metaproterenol)
Study: 8239103
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg methylprednisolone acetate suspension
Study: 25972203
Drug: CrossFit Teens™
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrossFit Teens™ resistance training programme (60 min, twice per week for 8 weeks)
Study: 25939638
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.1 mg/kg body weight) and nitrous oxide‐oxygen sedation
Study: 25939638
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.2 mg/kg body weight) and nitrous oxide‐oxygen sedation
Study: 16421476
Drug: Carvedilol 12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5-25 mg
Study: 11545670
Drug: General medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: General medicine clinic (n = 61)
Study: 9259053
Drug: Aminophylline (nonspecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (nonspecific competitive adenosine receptor antagonist)
Study: 2573572
Drug: Somatostatin (250-micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (250-micrograms bolus and 250-micrograms per hr infusion, with repeat bolus and doubling of the infusion if bleeding was not controlled)
Study: 1026339
Drug: Intensive-chemotherapy schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive-chemotherapy schedule
Study: 19889003
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy alone
Study: 20521030
Drug: Baclofen (60,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (60, 90 mg/day) for 16 days
Study: 20521030
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg/day) for 14 days
Study: 16002558
Drug: Cimetidine (2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (2.3 mg/min over 50 min)
Study: 31036625
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 6 months (Q6M)
Study: 31036625
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 3 months (Q3M)
Study: 20446755
Drug: Leukotriene receptor
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene receptor antagonists (LTRAs)
Study: 15673691
Drug: MCI-196 6
Normalized name: kaolin 196 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCI-196 6 g/day
Study: 12627359
Drug: Oral valacyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir, 2 g q.i.d.
Study: 12627359
Drug: Intravenous ganciclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week
Study: 27492941
Drug: Cardiac rehabilitation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac rehabilitation (12 weeks of physical exercise and monthly psycho-educational consultations)
Study: 18678160
Drug: Blood-letting puncture
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-letting puncture plus red-hot needle therapy
Study: 16450688
Drug: Tramadol 37.5
Normalized name: ACETAMINOPHEN 325MG/TRAMADOL 37.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 37.5 mg/APAP 325 mg (mean, 4.3 tablets)
Study: 16450688
Drug: Codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 30 mg/APAP 300 mg (mean, 4.6 tablets)
Study: 12891252
Drug: G‐CSF (filgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (filgrastim) 5 mg/kg/day
Study: 1678735
Drug: Metadoxine 900
Normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metadoxine 900 mg twice daily eluted in 500 ml of saline infusion
Study: 1678735
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 500 ml of saline infusion twice daily with equivalent doses of pyridoxine (40 mg/die) every morning
Study: 29698106
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of MS-Contin (morphine)
Study: 30758402
Drug: Iodoform paste
Normalized name: Iodoform
DrugBank: Iodoform (DB13813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodoform paste (iodoform + camphorated parachlorophenol + ointment comprising prednisolone acetate 5.0 mg and rifamycin 1.5 mg)
Study: 29046518
Drug: Oxycodone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.05 mg/kg)
Study: 18418361
Drug: Memantine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (40 mg)
Study: 17314582
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of ultracain
Study: 11196267
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 5.0 microg/kg per day
Study: 11196267
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 10.0 microg/kg per day
Study: 9281302
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine daily
Study: 8052927
Drug: Pulse methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulse methylprednisolone (400 mg/day)
Study: 8052927
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (50 mg/day)